As a tumour-suppressing drug, Bri was proven to restrain the growth of human prostate cancer cell line PC-3-LUC by regulating phosphatidylinositol 3-kinase/Akt/NF-κB signalling and activating antitumor immunity by upregulating the level of interleukin-2 (Zeng et al. Here, AKT1 is linked to neoplasm.